Holliston, Mass. — Harvard Bioscience Inc. announced that it will close its manufacturing facility in Holliston as part of a broader consolidation of operations aimed at improving efficiency, streamlining production, and supporting long-term growth.
The life sciences equipment company said U.S. manufacturing currently based in Holliston will be transitioned to its manufacturing hub in Minneapolis, Minnesota, while certain product lines will be relocated to facilities in Germany, Sweden, and the United Kingdom. The moves are intended to align operations with each site’s center of excellence and improve logistics and execution.
The Holliston facility will remain operational throughout 2026 to ensure continuity for customers, with the consolidation expected to be completed by the first quarter of 2027. Harvard Bioscience said it has developed a phased transition plan to avoid disruptions to order fulfillment, product quality, and technical support.
“Building upon the enhanced flexibility provided by our recent refinancing, this consolidation represents a meaningful step forward in simplifying our manufacturing footprint and strengthening our operating model,” said John Duke, president and chief executive officer of Harvard Bioscience. “Concentrating our U.S. manufacturing and relocating certain operations internationally will better leverage the scale, capabilities, and expertise of our sites.”
The company expects the consolidation to generate approximately $3 million in cost savings in 2027 and about $4 million in annual savings beginning in 2028. Those savings are expected to come from reduced overhead, improved asset utilization, rationalization of product offerings, and targeted changes to the company’s workforce across affected operations.
Harvard Bioscience said the transition will result in incremental operating expenses during 2026 and the first half of 2027 as the company completes the relocation and restructuring process.
The company, which is publicly traded on the Nasdaq under the ticker HBIO, said additional details on the consolidation have been disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
Company officials said the restructuring is designed to improve throughput, speed time-to-market, and position Harvard Bioscience to operate more nimbly as it focuses on long-term value creation for customers and shareholders.
